

SAFETY DATA SHEETS


This SDS packet was issued with item:

078949190

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078928040 078942939

Safety Data Sheet



| 1. IDENTIFICATION | | | |
|---|---|---|---|
| <i>Product Information</i> | | | |
| Product name | KENALOG®-10, 40,80 mg/ml (triamcinolone acetonide) Injectable Suspension | | |
| Version | 3.0, 22.01.2020 | | |
| Jurisdiction | This Safety Data Sheet was prepared in accordance with the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) for the United States of America (USA) (CFR 1910.1200), European Union (EU) (EC 1272/2008) and United Nations (UN). The following countries utilize the UN GHS classification process: Mexico, Brazil, China, New Zealand, Canada, Japan, and Korea. | | |
| Active substance | Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11.beta.,16.alpha.)- | | |
| Synonyms | Sterile Triamcinolone Acetonide Suspension USP; Kenalog-10 Injection; Kenalog-40 Injection; Albicort; Kenacort; Kenalog-80 Injection; Adcortyl; Kenacort Retard; Kenacort-A; Kenacort-A10; Kenacort-A40; Kenacort-Im; Kenacort-T; Trigon | | |
| Intended Uses | This material is a finished drug product for patient use. This material is used to provide relief of inflammatory and pruritic skin conditions. | | |
| <i>Company/Undertaking Identification</i> | | | |
| Address | <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top;"> <u>USA</u> Bristol-Myers Squibb Company P.O. Box 191 New Brunswick, New Jersey 08903 United States of America 1-800-332-2056 </td> <td style="width: 50%; vertical-align: top;"> <u>Ireland</u> Bristol-Myers Squibb Company Cruiserath Road, Mulhuddart - Dublin 15 Cruiserath, Ireland MG-GBS-MSDS-Request@bms.com + 353.1.8854000 </td> </tr> </table> | <u>USA</u> Bristol-Myers Squibb Company P.O. Box 191 New Brunswick, New Jersey 08903 United States of America 1-800-332-2056 | <u>Ireland</u> Bristol-Myers Squibb Company Cruiserath Road, Mulhuddart - Dublin 15 Cruiserath, Ireland MG-GBS-MSDS-Request@bms.com + 353.1.8854000 |
| <u>USA</u> Bristol-Myers Squibb Company P.O. Box 191 New Brunswick, New Jersey 08903 United States of America 1-800-332-2056 | <u>Ireland</u> Bristol-Myers Squibb Company Cruiserath Road, Mulhuddart - Dublin 15 Cruiserath, Ireland MG-GBS-MSDS-Request@bms.com + 353.1.8854000 | | |
| Emergency Phone No. | <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top;"> USA (also Canada, Puerto Rico and the Virgin Island): 1-800-424-9300 Other Countries: See "Section 16" for country-specific emergency phone numbers from CHEMTREC. </td> <td style="width: 50%; vertical-align: top;"> <u>Ireland</u>: +(353)-19014670 </td> </tr> </table> | USA (also Canada, Puerto Rico and the Virgin Island): 1-800-424-9300 Other Countries: See "Section 16" for country-specific emergency phone numbers from CHEMTREC. | <u>Ireland</u> : +(353)-19014670 |
| USA (also Canada, Puerto Rico and the Virgin Island): 1-800-424-9300 Other Countries: See "Section 16" for country-specific emergency phone numbers from CHEMTREC. | <u>Ireland</u> : +(353)-19014670 | | |

| 2. HAZARDS IDENTIFICATION | |
|---|---|
| Classification and Labelling Common to All Jurisdictions | |
| Classification | Toxic To Reproduction - Reproductive Toxicity - Category 1A Toxic To Reproduction - Developmental Toxicity - Category 1A Effects On Or Via Lactation |
| Symbol | |
| Signal Word | Danger |
| Hazard Statements | May damage fertility (male reproductive toxicity, female reproductive toxicity) . May damage the unborn child (developmental toxicity) . May cause harm to breast-fed children. |

| 2. HAZARDS IDENTIFICATION | |
|--|---|
| Precautionary Statements | Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Avoid contact during pregnancy/while nursing. Use personal protective equipment as required. |
| Classification and Labelling for Specific Jurisdictions | |
| USA | |
| Classification | Specific Target Organ Systemic Toxicity (Repeated Exposure) - Category 1 |
| Hazard Statements | Causes damage to organs (adrenal glands, bone, muscle, gastrointestinal tract, immune system, eyes, nervous system, skin, female reproductive organs, male reproductive organs) through prolonged or repeated exposure. |
| Precautionary Statements | Do not breathe gas/fumes/vapour/spray/mist Wash thoroughly after handling. Do not eat, drink or smoke when using this product. |
| EU | |
| Classification | Specific Target Organ Systemic Toxicity (Repeated Exposure) - Category 2 |
| Hazard Statements | Repeated exposure may cause skin dryness or cracking. May cause damage to organs (adrenal glands, bone, muscle, gastrointestinal tract, immune system, eyes, nervous system, skin, female reproductive organs, male reproductive organs) through prolonged or repeated exposure. |
| Precautionary Statements | Do not breathe gas/fumes/vapour/spray/mist |
| UN | |
| Classification | Specific Target Organ Systemic Toxicity (Repeated Exposure) - Category 1 |
| Hazard Statements | Causes damage to organs (adrenal glands, bone, muscle, gastrointestinal tract, immune system, eyes, nervous system, skin, female reproductive organs, male reproductive organs) through prolonged or repeated exposure. |
| Precautionary Statements | Do not breathe gas/fumes/vapour/spray/mist Wash thoroughly after handling. Do not eat, drink or smoke when using this product. |

| 3. COMPOSITION/INFORMATION ON INGREDIENTS | | | | | |
|--|---------------|---------|-------------------------------|-----------|------------------------|
| Components | Concentration | CAS No. | EU only | | Other Registration No. |
| | | | EC No./REACH Registration No. | H-code(s) | |

| | | | | | |
|--|---------|------------------|-----------|---|----|
| <i>Hazardous components</i> | | | | | |
| Triamcinolone | 1 - 8 % | 76-25-5 | 200-948-7 | H360F H360D H362 H372 EUH 066 | -- |
| Acetonide | | | | | |
| <i>Other ingredients</i> | | | | | |
| Non-Hazardous Ingredients | > 90 % | Not available | -- | -- | -- |
| Other information: Sodium hydroxide and/or hydrochloric acid are used for pH adjustment. See section 16 for H-code text. | | | | | |

4. FIRST AID MEASURES

| | |
|----------------------|--|
| Eye contact | Rinse immediately with plenty of water for at least 15 minutes. Keep eye wide open while rinsing. If exposed or concerned: Get medical attention/advice. |
| Skin contact | Take off contaminated clothing and shoes immediately. Wash off immediately with plenty of water for at least 15 minutes. Discard contaminated clothing or wash before re-use. If exposed or concerned: Get medical attention/advice. |
| Inhalation | Move to fresh air. Oxygen or artificial respiration if needed. If exposed or concerned: Get medical attention/advice. |
| Ingestion | Do NOT induce vomiting. Never give anything by mouth to an unconscious person. If exposed or concerned: Get medical attention/advice. |
| Notes to Physician | Medical conditions aggravated include: diabetes, liver disorders, infection, immunodeficiency, hypertension, myasthenia gravis, osteoporosis, peptic ulcer, psychotic disorders, colitis, kidney disorders, idiopathic thrombocytopenic purpura. This product has been reported to interact with the following medications: aminoglutethimide, amphotericin B, drugs that decrease serum potassium concentration, antibiotics, anticholinesterases, anticoagulants, antidiabetics, antitubercular drugs, cholestyramine, diuretic, cyclosporine, immunosuppressants, NSAID (non-steroidal antiinflammatory drugs), drugs metabolized by cytochrome P-450, drugs that cause hyperglycemia, oral hypoglycemic drugs, neuromuscular blocking agents, fluoroquinolone antibiotics, certain vaccines, drugs that inhibit cytochrome P-450, estrogen, ketoconazole. Refer to Section 11. |
| Medical Surveillance | The need for a pre-placement, follow-up physical examination and history for employees with potential exposure to this compound is to be evaluated by a physician that is thoroughly knowledgeable about both the toxicity of this compound and the extent of work place exposure. Baseline testing would include: blood glucose test, a complete blood count with differential, a blood test for liver function, a blood test for kidney function. Based on opportunity for exposure and duration of exposure a periodic follow-up examination may be considered. Employees who are pregnant, are breast-feeding, or who are concerned with other reproductive issues should be encouraged to consult with the occupational health physician monitoring worker's health. |

5. FIRE-FIGHTING MEASURES

| | |
|----------------------|--|
| Flammable Properties | Not available |
| Extinguishing Media | Suitable extinguishing media: Dry chemical, Water spray, Foam Unsuitable extinguishing media: Do NOT use water jet. |

5. FIRE-FIGHTING MEASURES

| | |
|----------------------------|---|
| Protection of Firefighters | <p>Specific hazards: Refer to HAZARDS IDENTIFICATION section for a description of hazards for this material.</p> <p>Protective equipment: Use personal protective equipment. In the event of fire, wear self-contained breathing apparatus.</p> <p>Hazardous Combustion Products: carbon oxides (COx), hydrogen halides</p> <p>Further Information: HCl gas can form flammable or explosive mixtures with alcohols or metals. In the event of fire and/or explosion do not breathe fumes.</p> |
| Other information | Decontaminate protective clothing and equipment before reuse. |

6. ACCIDENTAL RELEASE MEASURES

| | |
|---------------------------|--|
| Personal precautions | Refer to protective measures listed in sections 7 and 8. Use personal protective equipment. Examples include tightly fitting safety goggles, lab coat and impervious gloves. Wear respiratory protection. Depending on the nature of the spill (quantity and extent of spill) additional protective clothing and equipment such as a self-contained breathing apparatus may be needed. |
| Environmental precautions | Prevent release to drains and waterways. Prevent release to the environment. |
| Containment Methods | Contain spillage, and then collect with non-combustible absorbent material, (e.g. sand, earth, diatomaceous earth, vermiculite) and place in container for disposal according to local / national regulations (see section 13). |
| Cleanup Methods | Contain and collect spillage and place in container for disposal according to local regulations (see Section 13). Clean area with detergent and water after spill pick-up, if appropriate. Handle waste materials, including gloves, protective clothing, contaminated spill cleanup material, etc., as appropriate for chemically and pharmacologically similar materials. |

7. HANDLING AND STORAGE

| | |
|------------------------|--|
| Handling Precautions | Avoid exposure - obtain special instructions before use. Avoid inhalation of vapour or mist. Keep away from heat and sources of ignition. Prevent release to drains and waterways. |
| Container Requirements | Store in sturdy containers appropriate to maintain the integrity of this material for its intended use. Store in spill containment pallet or other device to confine spills. |
| Storage Conditions | Store at room temperature. Protect against light. Keep away from heat, sparks and flames. Store locked up. |
| Specific use(s) | Refer to Section 1 |

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

| Exposure limit(s) | Company Guideline | ACGIH | Germany OEL | UK MEL |
|-------------------------|--|-------|-------------|--------|
| Triamcinolone Acetonide | 1 µg/m ³ 8 hour-TWA | -- | -- | -- |
| Benzyl Alcohol | | -- | -- | -- |
| Benzyl Alcohol | Occupational Exposure Limits have been established by: - Czech Republic - Poland - Latvia | | | |

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

| | |
|---|--|
| Recommended Industrial Hygiene Monitoring Methods | General - The health hazard risk of handling this material is dependent on many factors, including physical form, % API in material being handled, duration and frequency of process task, and effectiveness of controls. If it is necessary to handle this compound outside of engineering controls, an exposure risk assessment should be conducted and procedures documented by a qualified EHS professional. |
|---|--|

EXPOSURE CONTROLS / PERSONAL PROTECTION FOR MATERIAL AS SUPPLIED

This formulation contains an active pharmaceutical ingredient (API) with the guideline limit noted above. To keep the API below the recommended guideline, the material as supplied should be controlled during handling to limit total airborne aerosol exposure to: 12.5 µg/m³ (Material is assigned to Exposure Control Band 3 (range 10-< 100 µg/m³)).

| | |
|--------------------------------------|--|
| Engineering Controls and Ventilation | FOR MANUFACTURING PROCESSES (BULK): Use process enclosures, containment technology, or other engineering controls to keep airborne levels below recommended exposure limit. When handling quantities up to 150 milligrams, a standard laboratory with general laboratory dilution ventilation (e.g. 6-12 air changes per hour) is appropriate. When handling quantities from 150 milligrams to 1 kilogram, work in a standard laboratory using a fume hood; biological safety cabinet(Class II, all types); and, approved vented enclosure. Quantities exceeding 1 kilogram should be handled in a designated laboratory using laminar flow/powder containment booth. When handling solutions with low energy operations (pipette transfers, pouring, low velocity stirring, fraction collection, etc.) use protective shielding to limit the spread of splash or splatter. For manufacturing and pilot plant operations, use direct coupling and closed transfer systems for all bulk transfers. Use dust tight valves as appropriate. HEPA filtration of local exhaust ventilation (LEV) is required. FOR CLINICAL SETTING USE (DRUG PRODUCT): When handling small quantities in a clinical setting, good room ventilation is desirable. Specific engineering controls should not be needed. |
|--------------------------------------|--|

| | |
|------------------------|---|
| Respiratory protection | Use and selection of respiratory protection is based upon engineering controls in use and potential for aerosol generation. When engineering controls are not sufficient control exposure, wear an approved respirator with NIOSH Class 100 or high efficiency particulate (HEPA) filters or cartridges (EN 140/EN 136) when exposures are up to 10 times the exposure control guideline. Wear a loose-fitting (Tyvek or helmet type) HEPA powered-air purifying respirator (PAPR) (EN 12941) when exposures are 10-25 times the exposure control guideline. Wear a full facepiece negative pressure respirator with Class 100 or HEPA filters (EN 136) when exposures are 25-50 times the exposure control guideline. Wear a tight-fitting, full facepiece HEPA PAPR (EN 12942) when exposures are 50-100 times the exposure control guideline. Wear a hood-shroud HEPA PAPR (EN 12941) or full facepiece supplied air respirator (EN 139) operated in a pressure demand or other positive pressure mode when exposures are 100-1000 times the exposure control guideline. |
|------------------------|---|

| | |
|----------------|---|
| Eye protection | Safety glasses with side-shields are recommended (EN 166). Face shields or chemical safety goggles (EN 166) may be required if splash potential exists or if corrosive materials are present. Note: Choice of eye protection may be influenced by the type of respirator which is selected. |
|----------------|---|

| | |
|-----------------|---|
| Hand protection | Impervious nitrile, rubber and latex gloves are recommended (EN 420, EN 374). If material is handled in solution, the solvent should also be considered when selecting protective clothing material. Please note that employees who are allergic to natural rubber latex should use nitrile gloves. |
|-----------------|---|

| | |
|--------------------------|---|
| Skin and body protection | Wear a laboratory coat (EN 340) when handling quantities up to 1 kilogram. For quantities over 1 kilogram, wear laboratory coat(EN 340)or coverall of low permeability (EN 1149-1). For manufacturing operations, wear coverall of low permeability (EN 465/1149-1). For manufacturing operations, wear coverall of low permeability. |
|--------------------------|---|

| | |
|---------|---|
| Hygiene | Wash hands and face before breaks and immediately after handling the product. |
|---------|---|

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Environmental exposure controls Prevent release to drains and waterways.

9. PHYSICAL AND CHEMICAL PROPERTIES

General Information

Appearance

| | |
|----------------|--------------------|
| Physical State | liquid |
| Color | white to off-white |
| Form | suspension |

Odour

| | |
|----------------|-----------------|
| Odour | Not remarkable. |
| Odor Threshold | Not available |

Important health safety and environmental information

| | |
|----|-------|
| pH | 5 - 7 |
|----|-------|

Other information

| | |
|---|------------------|
| Bulk density | Not available |
| Evaporation rate | Not available |
| Molecular formula | Not applicable |
| Hydrolysis/Photolysis | Not available |
| Hygroscopicity | Not available |
| Molecular Weight | Not applicable |
| Log Octanol/Water Partition Coefficient [log Kow] | Not available |
| Surface Tension | Not available |
| pKa | Not available |
| Particle Size | Not available |
| Solubility, Water | soluble |
| Specific Gravity/ Relative density | 1.015 |
| Viscosity, dynamic | similar to water |
| Viscosity, kinematic | Not available |
| % Volatile | Not available |

Thermal/Stability properties

| | |
|--------------------------|---------------|
| Autoignition temperature | Not available |
| Boiling Point | 100 °C |
| Thermal decomposition | Not available |
| Explosive Limits, LEL | Not available |
| Explosive limits, UEL | Not available |
| Explosiveness | Not available |
| Flammability | Not available |
| Flash point | Not available |
| Melting Point | 0 °C |
| Oxidizing Potential | Not available |

Vapor Properties

| | |
|-------------------------------|--|
| Vapor Density | (Air =1): If adequate temperatures caused material to volatize, its vapor density would be much greater than 1. (Heavier than air) |
| Vapor Pressure | Not available |
| Saturated Vapor Concentration | Not available |

10. STABILITY AND REACTIVITY

Stability

| | |
|----------------------------------|---|
| Chemical Stability | Stable under normal conditions. |
| Conditions to avoid | Not available |
| Materials to avoid | Not available |
| Hazardous decomposition products | Hazardous decomposition products formed under fire conditions.: carbon oxides (COx), hydrogen halides |
| Hazardous reactions | Not available |

Sensitivity to static discharge/Dust exp.

| | |
|--------------------|----------------|
| Summary Statements | not applicable |
|--------------------|----------------|

11. TOXICOLOGICAL INFORMATION

| | |
|------------------------|---|
| Routes of Entry | Ingestion, inhalation, Eye contact, Skin contact |
| Eye Irritation | <u>Triamcinolone Acetonide</u> Mildly and/or transiently irritating to eyes |
| Skin Irritation | <u>Triamcinolone Acetonide</u> Repeated exposure may cause skin dryness or cracking. skin thinning |
| Respiratory Irritation | <u>Triamcinolone Acetonide</u> Mildly and/or transiently irritating to respiratory tract. |
| Sensitization | <u>Triamcinolone Acetonide</u> Not a dermal sensitizer Allergic contact dermatitis is quite rare but has been reported. |
| Acute Toxicity Study | Acute Oral <u>Triamcinolone Acetonide</u> LD50 (mouse): 5,000 mg/kg Acute toxicity (other routes of administration) <u>Triamcinolone Acetonide</u> LD50 (rat, subcutaneous): 13.1 mg/kg LD50 (mouse, subcutaneous): 132 mg/kg LD50 (mouse, intraperitoneal): 105 mg/kg |

| 11. TOXICOLOGICAL INFORMATION | | | |
|--------------------------------------|---|-------------|------------|
| Repeated Dose Toxicity | Not available | | |
| Genetic Toxicity | <u>Triamcinolone Acetonide</u> In vitro Ames reverse-mutation assay -- negative Forward gene mutation assay -- negative Mutagenicity Assessment Not classified as mutagen according to GHS criteria. | | |
| Carcinogenicity | <u>Triamcinolone Acetonide</u> 2 years oral (daily) rat study : Tumor NOAEL = 0.001 mg/kg No treatment-related tumors were observed. 2 years drinking water (daily) rat study : Tumor LOAEL = 0.0048 mg/kg [tumor organs: liver] 2 years oral (daily) mouse study : Tumor NOAEL = 0.003 mg/kg No treatment-related tumors were observed. Carcinogenicity Assessment Not classifiable as to its carcinogenicity to humans. | | |
| Carcinogenicity | ACGIH | IARC | NTP |
| Triamcinolone Acetonide | -- | -- | -- |
| Reproductive Toxicity | <u>Triamcinolone Acetonide</u> Assessment Reproductive Toxicity Several studies were conducted. Selective reproductive toxicant Maternal effects include: menstrual irregularities . Paternal effects include: sperm abnormalities See "Human Experience". See also "Developmental Toxicity" for information on reproductive effects. | | |
| Developmental Toxicity | <u>Triamcinolone Acetonide</u> Developmental Toxicity Assessment Several developmental studies were conducted. Birth defects were observed in animal studies. Compound may be toxic during early embryonic development. Selective developmental toxicant This compound and/or its metabolites may be excreted into the milk. May cause harm to breastfed babies. | | |
| Human experience | Experiences with Human Exposure <u>Triamcinolone Acetonide</u> General effects therapeutic use low exposure - acute effects include: muscle weakness, muscle pain, bone fractures, infection, oedema, headache, difficulty sleeping, vertigo, restlessness, euphoria, mental disturbance, depression, anxiety, mood changes, seizure disorders, nosebleeds, cough, fever, nausea, anaphylaxis, vomiting, anorexia, gastrointestinal disturbance, sore throat, dry mouth, taste disturbance, speech difficulty, congestion, redness and swelling of eyes, vision changes, facial swelling, allergic reactions, skin thinning, acne, redness and | | |

11. TOXICOLOGICAL INFORMATION

swelling of skin, hives, bruising, superficial burning sensation, tingling, increase in blood pressure, Cushing's syndrome, electrolyte disturbance, hyperglycemia, adrenocortical insufficiency, withdrawal symptoms, osteoporosis, bone effects, menstrual irregularities, impaired spermatogenesis, cataracts, glaucoma, nose changes, otitis, peptic ulcer, psychiatric disorders, pancreatitis, changes in white blood cell parameters, alopecia, asthma, growth retardation, skin effects, injection site reactions, cardiac disorders, death.

Target Organs Triamcinolone Acetonide
adrenal glands, bone, muscle, gastrointestinal tract, immune system, eyes, nervous system, skin, female reproductive organs, male reproductive organs

Symptoms Triamcinolone Acetonide
See "Human Experience".

Pharmacokinetics/
Toxicokinetics Triamcinolone Acetonide
Absorption: Data available upon request. This material was readily absorbed through the skin.
Distribution: Data available upon request.
Metabolism: Data available upon request.
Elimination: Half-life = 2 - 3 Hour(s) (Human).

Other Toxicity Information Not available

Other Information: This SDS may contain toxicological and/or pharmacological information derived from either the specified product or from compounds in the same pharmacological class.

12. ECOLOGICAL INFORMATION

Ecotoxicity effects

Acute Toxicity to Aquatic Invertebrates

Triamcinolone Acetonide
EC50 (Daphnia magna (Water flea), 48 H): > 100 mg/l.

Mobility Not available

Persistence and degradability

Biodegradation

Triamcinolone Acetonide
Ultimate aerobic biodegradation (28 D): 3 %; Not Readily Biodegradable - unlikely to undergo rapid biodegradation in the environment

PBT and vPvB assessment Not available

13. DISPOSAL CONSIDERATIONS

| | |
|----------------------------------|--|
| Advice On Disposal And Packaging | Disposal should be in accordance with applicable regional, national and local laws and regulations. Local regulations may be more stringent than regional or national requirements. This information presented only applies to the material as supplied. |
| Other information | Disposal by incineration is recommended. |

14. TRANSPORT INFORMATION

This material is not a dangerous good for the purpose of transportation in all modes.

15. REGULATORY INFORMATION

United States of America

313 Toxic Release Inventory No components listed on the SARA 313 inventory.

TSCA Inventory Not listed. Food, drug and cosmetic products are exempt from TSCA.

Regulatory Authorizations and Restrictions: Not available

16. OTHER INFORMATION

Text of H-code(s) mentioned in Section 3.

| | |
|---------|---|
| EUH 066 | Repeated exposure may cause skin dryness or cracking. |
| H360D | May damage the unborn child |
| H360F | May damage fertility |
| H362 | May cause harm to breast-fed children. |
| H372 | Causes damage to organs through prolonged or repeated exposure. |

Recommended Restrictions for Use:

Not available

SDS preparation information

Prepared by Global Environment, Health, Safety, and Sustainability 1-732-227-7380

Prepared on 22.01.2020 DD/MM/YYYY


This Safety Data Sheet has been revised. This data sheet contains changes from the previous version in section(s): 2, 8, 11, 15, and 16.

Other information

| | | |
|------|-------------------------------|---------------------|
| HMIS | Health | 2* |
| | Flammability | Not Determined (ND) |
| | Reactivity | Not Determined (ND) |
| | Personal protective equipment | See Section 8. |

NFPA

Health 2
 Fire ND
 Reactivity ND
 Special ND



Country- Specific Emergency Phone Numbers

| Country | Local # or Toll Free in Country* | Greeting Language | Country | Local # or Toll Free in Country* | Greeting Language |
|--------------------------|----------------------------------|-------------------------|--------------------------------|----------------------------------|----------------------------------|
| AMERICAS | | | Latvia (Riga) | +371-66165504 | Latvian |
| Argentina (Buenos Aires) | +54-1159839431 | Latin American Spanish | Lithuania (Vilnius) | +370-52140238 | Lithuanian |
| Brazil (Rio De Janeiro) | +55-2139581449 | Portuguese | Luxembourg | +352-20202416 | French, German, Luxembourgish |
| Cayman Islands | +1-345-749-8392 | English | Netherlands | +31-858880596 | Dutch |
| Chile (Santiago) | +56-225814934 | Latin American Spanish | Norway (Oslo) | +47-21930678 | Norwegian |
| Colombia * | 01800-710-2151 | Latin American Spanish | Poland (Warsaw) | +48-223988029 | Polish |
| Costa Rica * | +506-40003869 | Latin American Spanish | Portugal | +351-308801773 | Portuguese |
| Mexico * | 01-800-681-9531 | Latin American Spanish | Romania | +40-37-6300026 | Romanian |
| Panama | +507-8322475 | Latin American Spanish | Russia* | 8-800-100-6346 | Russian |
| Peru (Lima) | +51-17071295 | Latin American Spanish | Slovakia (Bratislava) | +421-233057972 | Slovak |
| Trinidad and Tobago* | +1-868-224-5716 | English | Slovenia (Ljubljana) | +386-10888016 | Slovene/Slovenian |
| EUROPE | | | Spain (Barcelona) | +34-931768545 | European Spanish |
| Austria (Vienna) | +43-13649237 | German | Spain* | 900-868538 | European Spanish |
| Belgium (Brussels) | +32-28083237 | French, Flemish, German | Sweden (Stockholm) | +46-852503403 | Swedish |
| Bulgaria (Plovdiv) | +359-32570104 | Bulgarian | Switzerland (Zurich) | +41-435082011 | Swiss German, French and Italian |
| Croatia (Zagreb) | +385-17776920 | Croatian | Turkey (Istanbul) | +90-212-7055340 | Turkish |
| Czech Republic (Prague) | +420-228880039 | Czech | Ukraine | +380-947101374 | Ukrainian |
| Finland (Helsinki) | +358-942419014 | Finnish | UK (London) | +44-870-8200418 | English |
| France | +33-975181407 | French | EAST ASIA | | |
| Germany * | 0800-181-7059 | German | China | 86-21-53235036 | Mandarin |
| Denmark | +45-69918573 | Danish | Hong Kong* | 800-968-793 | Cantonese |
| Estonia | +372-6681294 | Estonian | Japan | +81-345209637 | Japanese |
| Germany (Frankfurt) | +49-69643508409 | German | Singapore | +65-31581349 | English and Mandarin |
| Greece (Athens) | +30-2111768478 | Greek | South Korea | +82-070-7686-0086 | Korean |
| Hungary (Budapest) | +36-18088425 | Hungarian | AUSTRALIA & OCEANIA | | |
| Italy * | 800-789-767 | Italian | Australia (Sydney) | +61-290372994 | English |
| Italy (Milan) | +39-245557031 | Italian | New Zealand* | +64-98010034 | English |
| | | | India * | 000-800-100-7141 | Hindi |

*Phone numbers for countries marked with an asterisk must be dialed within the country.

The information contained in this SDS is believed to be accurate and represents the best information reasonably available at the time of preparation. However, we make no warranty, express or implied, with respect to such information, and we assume no liability from its use.